natgillin/translations-raw huggingface dataset:
What Pioglitazone Krka looks like and contents of the pack White to almost white round tablets with bevelled edges and with engraved "45" on one side of tablet (diameter 10.0 mm).
Izgled zdravila Pioglitazone Krka in vsebina pakiranja Bele do skoraj bele, okrogle tablete s prirezanimi robovi in z oznako ‘45' na eni strani (premer 10,0 mm).
Other medicines and Pioglitazone Krka
Druga zdravila in zdravilo Pioglitazone Krka
Do not take Pioglitazone Krka: - if you are allergic to pioglitazone or any of the other ingredients of this medicine (listed in section 6).
Pioglitazon je kontraindiciran pri bolnikih: - s preobčutljivostjo na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju
What Pioglitazone Krka looks like and contents of the pack White to almost white round tablets with bevelled edges and with engraved "15" on one side of tablet (diameter 7.0 mm).
Izgled zdravila Pioglitazone Krka in vsebina pakiranja Bele do skoraj bele, okrogle tablete s prirezanimi robovi in z oznako ‘15' na eni strani (premer 7,0 mm).
If you stop using Pioglitazone Krka tablets, your blood sugar may go up.
Če ste prenehali jemati zdravilo Pioglitazone Krka, se vam lahko raven krvnega sladkorja zviša, zato se posvetujte z zdravnikom, preden prenehate s tem zdravljenjem.
Frequencies are defined as: - Very common ( 1/10) - Common ( 1/100 to < 1/10) - Uncommon ( 1/1,000 to < 1/100) - Rare ( 1/10,000 to < 1/1,000) - Very rare (< 1/10,000) - Not known (cannot be estimated from the available data)
Neželeni učinki, o katerih so poročali večkrat (> 0,5%) kot pri placebu in več kot enkrat pri bolnikih, ki so prejemali pioglitazon v dvojno slepih študijah, so našteti spodaj, in sicer po razredih organskih sistemov in absolutni pogostnosti, kot je priporočeno po MedDRA. Pogostnosti so določene kot: - zelo pogosti (≥ 1/10), - pogosti (≥ 1/100 do < 1/10), - občasni (≥ 1/1.000 do < 1/100), - redki (≥ 1/10.000 do < 1/1.000), - zelo redki (< 1/10.000),
Combination with metformin with sulphonylurea with metformin and sulphonylurea with insulin fatigue uncommon
Kombinacija z metforminom s sulfonilsečnino z metforminom in sulfonilsečnino z insulinom aminotransferaze
The other side effects that have been experienced by some patients taking Pioglitazone Krka are:
Pri nekaterih bolnikih, ki so jemali zdravilo Pioglitazone Krka, so se pojavili drugi neželeni učinki:
Adverse reactions reported in excess (> 0.5%) of placebo and as more than an isolated case in patients receiving pioglitazone in double-blind studies are listed below as MedDRA preferred term by system organ class and absolute frequency.
Neželeni učinki, o katerih so poročali večkrat (> 0,5%) kot pri placebu in več kot enkrat pri bolnikih, ki so prejemali pioglitazon v dvojno slepih študijah, so našteti spodaj, in sicer po razredih organskih sistemov in absolutni pogostnosti, kot je priporočeno po MedDRA. Pogostnosti so določene kot: - zelo pogosti (≥ 1/10), - pogosti (≥ 1/100 do < 1/10), - občasni (≥ 1/1.000 do < 1/100), - redki (≥ 1/10.000 do < 1/1.000),
General disorders and administration site conditions oedema very common fatigue uncommon
Motnje reprodukcije in dojk erektilna disfunkcija Splošne težave in spremembe na mestu aplikacije edem zelo pogosti utrujenost občasni
Pioglitazone Krka tablets should be used every day to work properly.
Če ste prenehali jemati zdravilo Pioglitazone Krka Za pravilno delovanje je potrebno zdravilo Pioglitazone Krka jemati vsak dan.
Tel: + 49 (0) 4721 606-0
TAD Pharma GmbH Tel: + 49 (0) 4721 606-0
Combination with metformin with sulphonylurea with metformin and sulphonylurea with insulin blood creatine phospho-kinase increased common increased lactic dehydro-genase uncommon
Kombinacija z metforminom s sulfonilsečnino z metforminom in sulfonilsečnino z insulinom novotvorbe (vključno s cistami in polipi) rak mehurja občasni občasni občasni občasni občasni
Localised swelling (oedema) has also been experienced very commonly in patients taking Pioglitazone Krka in combination with insulin.
Pri bolnikih, ki so jemali Pioglitazone Krka v kombinaciji z insulinom, je bilo zelo pogosto ugotovljeno lokalno otekanje (edemi).
Reproductive system and breast disorders erectile dysfunction common
Bolezni dihal, prsnega koša in mediastinalnega prostora dispneja
- Your kidneys do not work properly.
Vaše ledvice ne delujejo pravilno.
• Activated Clotting Time (ACT)
• Aktivirani čas strjevanja (ACT)
There are no adequate and well-controlled studies in pregnant women.
Ustreznih in dobro nadzorovanih študij pri nosečnicah ni.
Your doctor will discuss with you the risks and benefits of using this medicine.
Vaš zdravnik se bo z vami pogovoril o tveganjih in koristih tega zdravila.
Odds Ratio (95% CI)
Razmerje verjetnosti (95-% IZ)
Therefore interpretation of these observational studies is limited and an association between aprotinin use and increased mortality can neither be established nor refuted.
Zato je razlaga izsledkov teh opazovalnih študij omejena, povezave med uporabo aprotinina in povečano umrljivostjo pa ni mogoče niti potrditi, niti ovreči.
For adult patients the following dose regimen is recommended:
Za odrasle bolnike se priporoča naslednji režim odmerjanja
asthma (bronchospasm)
astma (bronhospazem)
Most of the studies did not adequately account for these baseline differences in risk factors and the influence of these risk factors on the results is not known.
V večini študij niso namenili dovolj pozornosti razlikam v izhodiščnih dejavnikih tveganja, vpliv teh dejavnikov tveganja na izsledke pa ni znan.
Adequate anticoagulation with heparin must be assured (see also above).
Zagotoviti je treba ustrezno antikoagulacijo s heparinom (glejte tudi zgoraj).
4.9 Overdose There is no specific antidote.
4.9 Preveliko odmerjanje Specifičnega antidota ni.
<Aprotinin-containing medicinal product> belongs to a group of medicines called anti-fibrinolytics, i.e. medicines to prevent blood loss.
<Zdravilo, ki vsebuje aprotinin>, spada v skupino zdravil, imenovanih antifibrinolitiki, tj. zdravila, ki preprečujejo izgubo krvi.
It is unknown whether aprotinin is excreted in human milk.
Ni znano, ali se aprotinin izloča v materino mleko.
Assessment of potential for allergic reactions
Ocena možnih alergijskih reakcij
In total, about 11% of aprotinin-treated patients experienced adverse reactions.
Skupno so se pri približno 11 % bolnikov, zdravljenih z aprotininom, pojavili neželeni učinki.
Animal studies did not provide any evidence of teratogenic or other embryotoxic effects of aprotinin.
Študije na živalih niso pokazale nobenega dokaza o teratogenih ali drugih embriotoksičnih učinkih aprotinina.
An association between aprotinin use and increased mortality has been reported in some nonrandomized observational studies (eg, Mangano 2007, Schneeweiss 2008, Olenchock 2008, Shaw 2008) while other non-randomized studies have not reported such an association (eg, Karkouti 2006, Mangano 2006, Coleman 2007, Pagano 2008, Ngaage 2008, Karkouti, 2009).
V nekaterih nerandomiziranih opazovalnih študijah so poročali o povezavi med uporabo aprotinina in povečano umrljivostjo (npr. Mangano 2007, Schneeweiss 2008, Olenchock 2008, Shaw 2008), medtem ko v drugih nerandomiziranih študijah niso poročali o taki povezavi (npr. Karkouti 2006, Mangano 2006, Coleman 2007, Pagano 2008, Ngaage 2008, Karkouti, 2009).
The placenta is probably not absolutely impermeable to aprotinin, but permeation appears to take a very slow course.
Placenta najbrž ni povsem neprepustna za aprotinin, vendar ga prepušča zelo počasi.
Adult:
Odrasli
Mortality Information on mortality from randomized clinical trials is provided in section 5.1.
Umrljivost Podatki o umrljivosti iz randomiziranih kliničnih preskušanj so navedeni v poglavju 5.1.
If allergic reactions occur during injection or infusion, administration should be stopped immediately.
Če se pojavijo alergijske reakcije med injiciranjem ali infundiranjem, je treba z aplikacijo takoj prenehati.
Aprotinin should be used throughout pregnancy only if the potential benefit justifies the potential risk.
Aprotinin se lahko uporablja med nosečnostjo samo, če je pričakovana korist večja od možnega tveganja.
It is also used to reduce the need for a blood transfusion during and after heart surgery.
Uporablja se tudi za zmanjševanje potrebe po transfuziji krvi med in po operaciji srca.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you are given this medicine.
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte s svojim zdravnikom, preden prejmete to zdravilo.
Any residual solution should not be kept for later use.
Ostankov raztopine se ne sme shranjevati za kasnejšo uporabo.
Paediatric population The safety and efficacy in children below 18 years of age have not been established.
Pediatrična populacija Varnost in učinkovitost aprotinina pri otrocih, mlajših od 18 let, nista bili dokazani.
The safety and efficacy of <Aprotinin-containing medicinal product> in children below the age of 18 years have not been established.
Varnost in učinkovitost <zdravila, ki vsebuje aprotinin> pri otrocih, mlajših od 18 let, nista bili dokazani.
Pharmacotherapeutic group: Antihemorrhagics, proteinase inhibitors, ATC code: B02AB01
Farmakoterapevtska skupina: antihemoragiki, zaviralci proteinaz, oznaka ATC: B02AB01
In-hospital Mortality in a pool of Randomized Clinical Trials (Population: All Global CABG Patients Valid for Safety)
Hospitalna umrljivost v zbiru podatkov iz randomiziranih kliničnih preskušanjih (populacija: vsi CABG bolniki, primerni za oceno varnosti)
A trend of increased incidence of MI in association with aprotinin was observed in some studies, while other studies showed a lower incidence compared to placebo.
Tendenco povečane incidence miokardnega infarkta v povezavi z aprotininom so opazili v nekaterih študijah, medtem ko so v drugih študijah ugotovili manjšo incidenco v primerjavi s placebom.
Aprotinin is a broad spectrum protease inhibitor which has antifibrinolytic properties.
Aprotinin je širokospektralni zaviralec proteinaz, ki ima antifibrinolitične lastnosti.
Mortality For the risk of mortality associated with the use of aprotinin see section 4.4.
Umrljivost Glede tveganja za umrljivost, povezano z uporabo aprotinina, glejte poglavje 4.4.
4.7 Effects on ability to drive and use machines Not relevant.
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji
Therefore, administration of aprotinin is contraindicated in these patients.
Uporaba aprotinina je pri teh bolnikih kontraindicirana.
In rats, guinea-pigs, rabbits and dogs, high doses (>150.000 KIU/kg) injected quickly caused a blood pressure reduction of varying magnitude, which rapidly subsided.
Pri podganah, morskih prašičkih, kuncih in psih so hitro injicirani veliki odmerki (> 150.000 k.i.e./kg), povzročili različno izrazito znižanje krvnega tlaka, ki se je hitro popravilo.
It also inhibits the contact phase activation of coagulation which both initiates coagulation and promotes fibrinolysis.
Aprotinin zavira tudi kontaktno fazo aktivacije koagulacije, kar sproži koagulacijo in pospešuje fibrinolizo.
Other medicines and <Aprotinin-containing medicinal product> Tell your doctor if you are taking, have recently taken or might take any other medicines.
Druga zdravila in <zdravilo, ki vsebuje aprotinin> Obvestite svojega zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Re-exposure to aprotinin
Ponovna izpostavljenost aprotininu
If there are no signs of allergy, you will be given 100-200 ml <Aprotinin-containing medicinal product> over 20 to 30 minutes, followed by 25 - 50 ml per hour (max. 5 - 10 ml/min) until the end of the operation.
Če ni znakov alergije, boste prejeli 100 - 200 ml <zdravila, ki vsebuje aprotinin>, v 20 do 30 minutah, nato pa 25 - 50 ml na uro (maks.
In these studies, aprotinin was usually administered to patients who had more risk factors for increased mortality before surgery than patients in the other treatment groups.
V teh študijah so aprotinin običajno dali bolnikom, ki so imeli pred kirurškim posegom več dejavnikov tveganja za povečano umrljivost kot bolniki v drugih skupinah.
When using a multi-lumen central catheter a separate catheter is not required.
Kadar se uporablja večcevni centralni kateter, ni treba uporabiti ločenega katetra.
Aminoglycosides are a risk factor for renal dysfunction.
Aminoglikozidi so dejavnik tveganja za motnje v delovanju ledvic.
A special dose adjustment is not warranted.
Posebno prilagajanje odmerka ni potrebno.
Aprotinin should only be used after careful consideration of the benefits and risks, and the consideration that alternative treatments are available (see section 4.4 and 5.1).
Aprotinin se lahko uporablja le po skrbni oceni koristi in tveganj ter ob upoštevanju, da so na voljo tudi druga zdravljenja (glejte poglavji 4.4 in 5.1).
All patients treated with aprotinin should first receive a test dose to assess the potential for allergic reactions (see section 4.2).
Vsi bolniki, ki so bili zdravljeni z aprotininom, morajo najprej dobiti testni odmerek za oceno možnih alergijskih reakcij (glejte poglavje 4.2).
In case of re-exposure the incidence of allergic/anaphylactic reactions may reach the five percent level.
Pri ponovni izpostavljenosti aprotininu lahko incidenca alergijskih/anafilaktičnih reakcij doseže 5 %.
• Determination of Heparin Levels
• Metoda za določanje heparina
Studies in patients with renal impairment revealed no clinically significant pharmacokinetic alterations or obvious side effects.
V študijah pri bolnikih z okvaro ledvic niso ugotovili klinično pomembnih farmakokinetičnih sprememb ali očitnih neželenih učinkov.
In general, you will not be given more than 700 ml of <Aprotinin-containing medicinal product> at any one time.
Naenkrat vam ne bodo dali več kot 700 ml <zdravila, ki vsebuje aprotinin>.
However, since aprotinin is not bioavailable after oral administration, any drug contained in the milk is not expected to have a systemic effect on the breast-feed child.
Ker aprotinin po peroralni uporabi ni biološko razpoložljiv, ni pričakovati, da bi imelo zdravilo v materinem mleku sistemski učinek na dojenega otroka.
The most serious adverse reaction was myocardial infarction.
Najbolj resen neželeni učinek je bil miokardni infarkt.
Hypersensitivity to the active substance or any of the excipients listed in section 6.1.
Preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
Therefore, the partial thromboplastin time (PTT) should not be used to maintain adequate anticoagulation with heparin.
Zato se za vzdrževanje ustrezne antikoagulacije s heparinom ne sme uporabljati delnega tromboplastinskega časa (PTT).
However, due to several methodological deficiencies no firm conclusion on cardiovascular risks can be made on the BART study results.
Vendar pa zaradi številnih pomankljivosti v metodologiji iz izsledkov BART študije ni možno dokončno opredeliti srčno-žilnega tveganja.
Daily doses of up to 100,000 KIU/kg did not interfere with the growth and development of the young, and doses of 200,000 KIU/kg/day were not teratogenic.
Dnevni odmerki do 100.000 k.i.e./kg niso vplivali na rast in razvoj mladičev, pa tudi odmerki 200.000 k.i.e./kg/dan niso bili teratogeni.
Aprotinin should be infused using a central venous catheter.
Aprotinin je treba infundirati skozi centralni venski kateter.
<Aprotinin-containing medicinal product> will only be given if your doctor has done blood tests before to check you are suitable (e.g. an appropriate aprotinin-specific IgG antibody test), otherwise other medicines may be a better option for you.
<Zdravilo, ki vsebuje aprotinin> boste prejeli šele, ko bo zdravnik opravil krvne preiskave in preveril, če ste primerni za zdravljenje (npr. ustrezen test na specifična protitelesa IgG proti aprotininu), sicer so za vas bolj primerna druga zdravila.
A standard loading dose of heparin, administered prior to cannulation of the heart, plus the quantity of heparin added to the prime volume of the cardiopulmonary bypass circuit, should total at least 350 IU/kg.
Skupni standardni začetni odmerek heparina pred kanilacijo srca, in količina heparina, dodana primarnemu volumnu kardiopulmonalnega obvoda, mora biti skupno vsaj 350 i.e./kg.
Metabolism, elimination and excretion
Presnova, odstranjevanje in izločanje
Elderly Reported clinical experience has not identified differences in responses in elderly patients.
Starejši Glede na klinične izkušnje, o katerih so poročali, v odzivu starejših bolnikov na zdravljenje ni razlik.
6.6 Special precautions for disposal and other handling Parenteral drug products should be inspected visually for particulate matter and colour change prior to administration.
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Pred uporabo je treba zdravilo za parenteralno uporabo vizualno pregledati, če so v njem delci in če se je spremenila barva.
A retrospective review showed that the incidence of an allergic/anaphylactic reaction following reexposure is increased when the re-exposure occurs within 6 months of the initial administration (5.0 % for re-exposure within 6 months and 0.9 % for re-exposures greater than 6 months).
Retrospektivni pregled podatkov je pokazal, da je incidenca alergijskih/anafilaktičnih reakcij po ponovni izpostavljenosti aprotininu večja, če pride do ponovne izpostavitve v roku 6 mesecev od prve uporabe zdravila (5,0 % za ponovno izpostavljenost v roku 6 mesecev in 0,9 % za ponovno izpostavljenost po 6 mesecih).
Fertility There are no adequate and well-controlled studies addressing fertility in men or women.
Plodnost Ustreznih in dobro nadzorovanih študij o vplivu zdravila na plodnost pri moških in ženskah ni.
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}>.
Navodilo je bilo odobreno <{MM/LLLL}><{mesec/LLLL}>.
It is recommended that your doctor/surgeon should, in addition to <Aprotinin-containing medicinal product>, administer heparin (a medicine used to prevent blood clots) before and during the operation.
Priporočljivo je, da vam vaš zdravnik/kirurg pred in med operacijo poleg <zdravila, ki vsebuje aprotinin> da tudi heparin (zdravilo, ki se uporablja za preprečevanje nastanka krvnih strdkov).
An ACT is not a standardized coagulation test, and different formulations of the assay are affected differently by the presence of aprotinin.
ACT ni standarden koagulacijski test; različni testi v prisotnosti aprotinina reagirajo različno.
Heparin levels during bypass should not be allowed to drop below 2.7 U/ml (2.0 mg/kg) or below the level indicated by heparin dose-response testing performed prior to administration of aprotinin.
Raven heparina v času obvoda ne sme biti nižja od 2,7 enot/ml (2,0 mg/kg) ali pod vrednostjo, določeno glede na odgovor na odmerek heparina, ugotovljen pred uporabo aprotinina.
The symptoms of an allergic reaction may include: breathing difficulties reduced blood pressure itching, rash and hives feeling sick
Simptomi alergijske reakcije lahko vključujejo: - težave z dihanjem - znižan krvni tlak - srbenje, izpuščaj in koprivnico
You will receive a small amount of <Aprotinin-containing medicinal product> (1 ml) before the operation begins, to test if you are allergic to the <Aprotinin-containing medicinal product>.
Pred začetkom operacije boste prejeli majhno količino <zdravila, ki vsebuje aprotinin> (1 ml); s tem bodo testirali, ali ste alergični na <zdravilo, ki vsebuje aprotinin>.
In case of severe adverse drug reactions (like anaphylactic reaction, heart arrest, etc.) and their consecutive therapeutic measures, damage to the foetus has to be taken into account for a risk/benefit evaluation.
V primeru hudih neželenih učinkov (npr. anafilaktične reakcije, srčnega zastoja, itd.) in zato potrebnih ukrepov, je treba pri oceni tveganja in koristi upoštevati tudi poškodbe ploda.
Administration of aprotinin, especially to patients who have received aprotinin (including aprotinin containing fibrin sealants) in the past requires a careful risk/benefit assessment because an allergic reaction may occur (see sections 4.3 and 4.8).
Pri uporabi aprotinina, zlasti pri bolnikih, ki so to zdravilo že kdaj prejeli (vključno s fibrinskimi lepili, ki vsebujejo aprotinin), je potrebna skrbna ocena razmerja tveganja in koristi, ker se lahko pojavijo alergijske reakcije (glejte poglavji 4.3 in 4.8).
Aprotinin must be given only to patients in the supine position and must be given slowly (maximum 5 - 10 ml/min) as an intravenous injection or a short infusion.
Aprotinin je treba aplicirati počasi (največ 5 do 10 ml/min) kot intravensko injekcijo ali kratkotrajno infuzijo.
- You have or suspect you have received aprotinin or aprotinin containing fibrin sealants in the last 12 months.
V zadnjih 12 mesecih ste prejeli ali sumite, da ste prejeli aprotinin ali fibrinska lepila, ki vsebujejo aprotinin.
Even when a second exposure to aprotinin has been tolerated without symptoms, a subsequent administration may result in severe allergic reactions or anaphylactic shock with, in very rare cases, fatal outcome.
Tudi v primerih, kadar se po drugi izpostavljenosti aprotininu niso pojavili simptomi, lahko naslednja uporaba povzroči hude alergijske reakcije in anafilaktični šok, v zelo redkih primerih pa tudi smrt.
The same lumen should not be used for the administration of any other medicinal product.
Za dajanje kateregakoli drugega zdravila se ne sme uporabiti ista cevka.
In the majority of instances, post-operative renal dysfunction was not severe and reversible.
V večini primerov je bila okvara ledvic po kirurškem posegu reverzibilna in ni bila huda.
Although allergic reactions are rare in patients receiving <Aprotinin-containing medicinal product> for the first time, patients who are given <Aprotinin-containing medicinal product> more than once may have an increased chance of an allergic reaction.
Čeprav so pri bolnikih, ki prvič dobijo <zdravilo, ki vsebuje aprotinin>, preobčutljivostne reakcije redke, je pri bolnikih, ki <zdravilo, ki vsebuje aprotinin> prejmejo več kot enkrat, povečano tveganje za alergijske reakcije.
Graft Conservation Blood drawn from the aprotinin central infusion line should not be used for graft preservation.
Krvi iz centralnega infuzijskega sistema za aprotinin se ne sme uporabljati za konzerviranje presadka.
If you have any further questions, ask the doctor/surgeon giving you <Aprotinin-containing medicinal product>.
Če imate dodatna vprašanja, se posvetujte s svojim zdravnikom/kirurgom, ki vam <zdravilo, ki vsebuje aprotinin>, daje.
By forming reversible stoichiometric enzyme-inhibitor complexes, aprotinin acts as an inhibitor of human trypsin, plasmin, plasma kallikrein and tissue kallikrein, thus inhibiting fibrinolysis.
S tvorbo reverzibilnih stehiometričnih kompleksov, ki inhibirajo delovanje encimov, zavira delovanje humanega tripsina, plazmina, plazemskega in tkivnega kalikreina ter tako zavira fibrinolizo.
Marketing Authorisation Holder and Manufacturer [See Annex I - To be completed nationally] {Name and address} <{tel}> <{fax}> <{e-mail}>
Imetnik dovoljenja za promet z zdravilom in izdelovalec [glejte Prilogo I - izpolni država članica] {Ime in naslov} <{tel.}> <{faks}> <{e-pošta}>
Common: ≥ 1/100 to < 1/10
≥ 1/1.000 to < 1/100
<Aprotinin-containing medicinal product> can help to reduce the amount of blood loss you have during and after heart surgery.
<Zdravilo, ki vsebuje aprotinin>, pomaga pri zmanjševanju izgube krvi med in po operaciji srca.
Your doctor will evaluate the dose of heparin based from the results from tests of your blood.
Vaš zdravnik bo določil odmerek heparina glede na izvide krvnih preiskav.
Aprotinin should not be used when CABG surgery is combined with another cardiovascular surgery because the benefit risk balance of aprotinin in other cardiovascular procedures has not been established.
Aprotinin se ne sme uporabljati, kadar je premostitev koronarne arterije (CABG) združena z drugim srčno-žilnim kirurškim posegom, ker razmerje tveganja in koristi pri uporabi aprotinina pri drugih srčno-žilnih posegih ni bilo dokazano.